Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), founded in 1988 and headquartered in Tarrytown, New York, is one of the world's leading biotechnology companies. It develops medicines using proprietary technology platforms, including its VelocImmune antibody engine and genetics research, across immunology, oncology, ophthalmology, cardiovascular, metabolic, and rare diseases. Its flagship products include Dupixent, an immunology blockbuster commercialized globally with Sanofi; EYLEA and EYLEA HD, its retinal franchise co-developed with Bayer; and Libtayo, its PD-1 immuno-oncology therapy. With roughly 50 clinical programs and a market capitalization in the range of $90 billion, Regeneron is widely followed by investors for its combination of mature commercial franchises and a deep late-stage pipeline. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, REGN advanced approximately 20%, moving from an adjusted close of about $790.74 on October 16, 2026, to about $952.40 on November 16, 2026. The advance was front-loaded: shares surged 13.3% on October 30 alone after third-quarter results, closing at $927.89 and setting a new 52-week high.
Over the last quarter, the picture is similar but slightly less dramatic. From a close near $805.93 in mid-August 2026 to roughly $952.40 in mid-November, REGN gained about 18%. Notably, the stock traded as low as the low $720s in early October before recovering, meaning the quarterly gain was almost entirely generated by the post-earnings rally in late October and early November. The overall trend has been upward, punctuated by a sharp single-day repricing following the earnings beat. From what I see, this concentration of gains highlights how earnings can reset expectations quickly.
The dominant catalyst was the company's third-quarter 2026 earnings report on October 30. Regeneron reported revenue of $5.12 billion, up 36% year over year and ahead of the roughly $4.6 billion consensus estimate. Non-GAAP earnings per share reached $20.07, up 70% year over year and well above analyst expectations near $16. GAAP EPS was $18.45, up 35%.
Growth was led by record quarterly sales of Dupixent, EYLEA HD, and Libtayo. Sanofi collaboration revenue reached an all-time high of $2.7 billion, with Regeneron's share of collaboration profits up 77% to $2.6 billion, reflecting Dupixent growth and the completion of a development-cost repayment to Sanofi. EYLEA HD U.S. sales rose 62% to $699 million, while Libtayo global sales climbed 51% in constant currency to $550 million. I’m watching this closely because collaboration revenue trends often signal longer-term momentum.
Sentiment was further supported by an expanded Sanofi alliance, under which Regeneron expects to record a $1 billion upfront payment in the fourth quarter. After the report, analysts raised targets: BofA lifted its price target to $1,030 (Buy), Cantor Fitzgerald to $980 (Overweight), and Baird to $875 (Neutral).
The broader multi-month trend reflects a business in a sustained upswing. Regeneron's third quarter marked a third consecutive quarter of double-digit growth in both revenue and earnings. The shift of U.S. patients from the legacy EYLEA product to EYLEA HD has helped preserve the retinal franchise's revenue even as biosimilar competition pressures the older formulation, with EYLEA HD now representing nearly two-thirds of U.S. retinal sales.
Pipeline momentum also contributed. During the quarter, Regeneron received U.S. approval for Pasatru in fibrodysplasia ossificans progressiva, secured a Japanese approval and a positive European regulatory opinion for Libtayo, and resubmitted its application for odronextamab in diffuse large B-cell lymphoma. These developments reinforced the narrative of a diversifying portfolio beyond the Dupixent and EYLEA franchises. One thing that stands out is how these approvals add layers of optionality.
Investors are closely watching the U.S. Food and Drug Administration decision on cemdisiran for generalized myasthenia gravis, expected in November 2026. If approved, it would be the first siRNA therapy for the condition. Regeneron's fourth-quarter 2026 results, expected in January 2027, will also be important, including the recognition of the $1 billion Sanofi upfront payment and continued trends in collaboration profits.
Additional factors include the potential approval of the EYLEA HD prefilled syringe, ongoing biosimilar competition and Roche's Vabysmo in retinal disease, and pipeline readouts across anticoagulation, obesity, and metabolic programs. The odronextamab regulatory decision expected in February 2027 is another milestone. These catalysts, rather than short-term price action, are likely to shape the stock's trajectory over the coming quarters.
In my analysis of stocks like REGN, I often turn to Tickeron’s AI Trading Bots to review how automated strategies have performed across similar names. These systems offer a data-driven way to gauge positioning without replacing my own research. They help surface patterns in volatility and momentum that complement traditional fundamental work, especially when tracking biotech names with event-driven moves.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
The 10-day moving average for REGN crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for REGN just turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 38 of 49 cases over the following month. The odds of a continued upward trend are 78%.
REGN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 203 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 185 of 264 cases where REGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
The 10-day RSI Indicator for REGN moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 20 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 49%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 64 cases where REGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 62%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on REGN as a result. In 48 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
REGN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 62 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.936) is normal, around the industry mean (3.592). P/E Ratio (21.599) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (131.305) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (442.120).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of medicines for the treatment of serious medical conditions
Industry Biotechnology